Top-Rated StocksTop-RatedNASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free LEGN Stock Alerts $47.45 +0.39 (+0.83%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$45.70▼$47.8550-Day Range$46.19▼$69.9952-Week Range$45.52▼$77.32Volume1.81 million shsAverage Volume919,694 shsMarket Capitalization$8.63 billionP/E RatioN/ADividend YieldN/APrice Target$83.26 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Legend Biotech alerts: Email Address Legend Biotech MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside75.5% Upside$83.26 Price TargetShort InterestBearish5.49% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 26 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.43) to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector465th out of 909 stocksPharmaceutical Preparations Industry208th out of 424 stocks 4.5 Analyst's Opinion Consensus RatingLegend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLegend Biotech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.49% of the outstanding shares of Legend Biotech have been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Legend Biotech has recently decreased by 4.95%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LEGN. Previous Next 1.9 News and Social Media Coverage News SentimentLegend Biotech has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Legend Biotech this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($1.43) to $0.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -32.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -32.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 6.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Legend Biotech Stock (NASDAQ:LEGN)Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Read More LEGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LEGN Stock News HeadlinesApril 24, 2024 | americanbankingnews.comLegend Biotech (NASDAQ:LEGN) Receives "Buy" Rating from HC WainwrightApril 23, 2024 | markets.businessinsider.comHold Rating on Legend Biotech Amidst Approval of Carvykti and Commercial Manufacturing ChallengesApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 22, 2024 | businesswire.comCARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaApril 20, 2024 | msn.comFDA requires labeling changes to CAR-T cell therapies to reflect cancer riskApril 19, 2024 | americanbankingnews.comHC Wainwright Weighs in on Legend Biotech Co.'s Q3 2024 Earnings (NASDAQ:LEGN)April 19, 2024 | americanbankingnews.comScotiabank Upgrades Legend Biotech (NASDAQ:LEGN) to "Sector Outperform"April 18, 2024 | americanbankingnews.comLegend Biotech (NASDAQ:LEGN) Reaches New 1-Year Low at $49.13April 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 18, 2024 | americanbankingnews.comQ1 2024 Earnings Forecast for Legend Biotech Co. (NASDAQ:LEGN) Issued By HC WainwrightApril 17, 2024 | seekingalpha.comScotiabank upgrades Legend Biotech to sector outperformApril 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Legend Biotech Amidst Anticipated Growth and Expanded Carvykti UseApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Legend Biotech Amidst Growth Prospects and CARVYKTI’s Market ExpansionApril 14, 2024 | nasdaq.comLEGN Quantitative Stock AnalysisApril 14, 2024 | nasdaq.comLegend Biotech is Now Oversold (LEGN)April 11, 2024 | businesswire.comLegend Biotech to Host Investor Conference Call on First Quarter 2024 ResultsApril 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)April 7, 2024 | markets.businessinsider.comBuy Rating on Legend Biotech: FDA Approval and Market Potential Bolster Carvykti’s OutlookApril 6, 2024 | finance.yahoo.comLegend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple MyelomaApril 5, 2024 | businesswire.comLegend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple MyelomaApril 3, 2024 | finance.yahoo.comShould You Continue to Hold Legend Biotech Corporation (LEGN)?April 2, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Shockwave Medical (SWAV), Veeva Systems (VEEV)April 1, 2024 | seekingalpha.comNatera and Alliance for Clinical Trials in Oncology announce activation of mid-stage trial in urothelial cancerMarch 31, 2024 | msn.comStock market bubble warnings are everywhere. These are the 10 most richly valued stocks right now.March 29, 2024 | finance.yahoo.comManagement’s Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4March 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Legend Biotech (LEGN)March 20, 2024 | benzinga.comGenScript Losses Shrink On Strong Growth For Cancer Cell TherapySee More Headlines Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today4/24/2024Next Earnings (Confirmed)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LEGN CUSIPN/A CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees1,800Year FoundedN/APrice Target and Rating Average Stock Price Target$83.26 High Stock Price Target$94.00 Low Stock Price Target$64.00 Potential Upside/Downside+75.5%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-518,250,000.00 Net Margins-181.75% Pretax Margin-182.41% Return on Equity-37.19% Return on Assets-25.34% Debt Debt-to-Equity Ratio0.22 Current Ratio6.92 Quick Ratio6.83 Sales & Book Value Annual Sales$285.14 million Price / Sales30.27 Cash FlowN/A Price / Cash FlowN/A Book Value$6.88 per share Price / Book6.90Miscellaneous Outstanding Shares181,910,000Free Float181,875,000Market Cap$8.63 billion OptionableOptionable Beta0.01 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Ying Huang Ph.D. (Age 51)CEO & Director Ms. Lori A. Macomber CPA (Age 53)Chief Financial Officer Mr. Doug WallaceVice President of Global OperationsDr. Guowei Fang Ph.D.Chief Scientific Officer & Head of Business DevelopmentJoanne ChoiSenior Manager of Investor RelationsMr. James Pepin J.D.General CounselDeborah WongExecutive Director of Strategic Marketing & Corporate CommunicationsMs. Elaine QianVP & Global Head of Human ResourcesDr. Yuhong Qiu Ph.D.Senior Vice President of Global Regulatory AffairsMr. Steven J. GavelSenior Vice President of Commercial Development, US & EuropeMore ExecutivesKey CompetitorsRoivant SciencesNASDAQ:ROIVAscendis Pharma A/SNASDAQ:ASNDCerevel TherapeuticsNASDAQ:CEREIntra-Cellular TherapiesNASDAQ:ITCIViking TherapeuticsNASDAQ:VKTXView All CompetitorsInstitutional OwnershipIFM Investors Pty LtdBought 3,712 shares on 4/22/2024Ownership: 0.002%Sumitomo Mitsui Trust Holdings Inc.Bought 1,443 shares on 4/19/2024Ownership: 0.090%Handelsinvest InvesteringsforvaltningSold 2,292 shares on 4/19/2024Ownership: 0.002%Matthews International Capital Management LLCSold 57,639 shares on 4/15/2024Ownership: 0.413%PNC Financial Services Group Inc.Sold 322 shares on 3/22/2024Ownership: 0.001%View All Institutional Transactions LEGN Stock Analysis - Frequently Asked Questions Should I buy or sell Legend Biotech stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LEGN shares. View LEGN analyst ratings or view top-rated stocks. What is Legend Biotech's stock price target for 2024? 12 brokers have issued twelve-month price objectives for Legend Biotech's stock. Their LEGN share price targets range from $64.00 to $94.00. On average, they expect the company's share price to reach $83.26 in the next year. This suggests a possible upside of 75.5% from the stock's current price. View analysts price targets for LEGN or view top-rated stocks among Wall Street analysts. How have LEGN shares performed in 2024? Legend Biotech's stock was trading at $60.17 on January 1st, 2024. Since then, LEGN shares have decreased by 21.1% and is now trading at $47.45. View the best growth stocks for 2024 here. When is Legend Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our LEGN earnings forecast. How can I listen to Legend Biotech's earnings call? Legend Biotech will be holding an earnings conference call on Monday, May 13th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Legend Biotech's earnings last quarter? Legend Biotech Co. (NASDAQ:LEGN) posted its earnings results on Monday, March, 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.30. The business had revenue of $76.50 million for the quarter, compared to analyst estimates of $95.63 million. Legend Biotech had a negative trailing twelve-month return on equity of 37.19% and a negative net margin of 181.75%. The business's revenue was up 177.2% on a year-over-year basis. What ETFs hold Legend Biotech's stock? ETFs with the largest weight of Legend Biotech (NASDAQ:LEGN) stock in their portfolio include Harbor Health Care ETF (MEDI), Global X MSCI China Health Care ETF (CHIH), Global X Genomics & Biotechnology ETF (GNOM), Matthews Emerging Markets Sustainable Future Active ETF (EMSF), Fidelity Disruptive Medicine ETF (FMED), KraneShares MSCI All China Health Care Index ETF (KURE), Tema Oncology ETF (CANC) and Virtus LifeSci Biotech Products ETF (BBP). What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY). When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Legend Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include Matthews International Capital Management LLC (0.41%), Sumitomo Mitsui Trust Holdings Inc. (0.09%), Handelsinvest Investeringsforvaltning (0.00%) and IFM Investors Pty Ltd (0.00%). How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LEGN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.